Large-scale analysis demonstrates the influence of CYP2C19 genotype on specific SSRI side effects.

doi:10.1038/s41397-026-00424-2

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Large-scale analysis demonstrates the influence of CYP2C19 genotype on specific SSRI side effects.

The pharmacogenomics journal - 5 Aug 2026

Eijsbouts Chris, Jiang Yunxuan, Ashenhurst James R, Granka Julie M, Pitts Steven, Auton Adam, Abul-Husn Noura S, Chubb Alison, Wu R Ryanne

Abstract excerpt

We evaluated the effect of CYP2C19 genotype on SSRI response in 114,627 research participants. We graded metabolizer status (0 for ultrarapid metabolizers to 4 for poor metabolizers), and regressed drug response outcomes on these grades. Among participants taking escitalopram or citalopram, slower metabolizers experienced side effects significantly more often than faster metabolizers (OR = 1.04 per grade,...

Topics

Humans
Cytochrome P-450 CYP2C19
Selective Serotonin Reuptake Inhibitors
Genotype
Female
Citalopram
Male
Escitalopram
Adult
Middle Aged

Source

Open in PubMed Open full text

Identifiers

PMID: 42552300
DOI: 10.1038/s41397-026-00424-2
PMCID: PMC13437230

Genes

CYP2C19

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics